ERBB2 and breast cancer: The underlying reasons for the better long-term DFS in HR-positive/HER2-low BC remain unclear, but potential factors may include the presence of HER2-enriched subtypes, reduced aggressiveness, and complex interactions between HR and HER2 [54].